epic update: observational study of first-line acalabrutinib treatment for cll
Published 1 year ago • 280 plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
3:29
how the management of cll is evolving
-
1:27
what is cll treatment research focused on?
-
2:39
updates from the phase i/ii bruin study: pirtobrutinib in cll
-
8:50
clinical trials vs observational studies
-
4:19
cll: what is 'watch & wait' and what can a patient do during this phase?
-
3:43
what is cll and how is it diagnosed?
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:15
exciting updates in cll and the importance of immune characterization
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:19
anbal-cel: updated results from phase i study of novel cd19-targeting car-t therapy
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
1:00
insights into the future of the cll treatment landscape
-
3:10
ascend: acalabrutinib in r/r cll
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:53
cll highlights from ash 2023: the flair study
-
2:00
associated toxicities of novel therapies for cll
-
1:18
celestial-tncll: ongoing phase iii study of sonrotoclax zanubrutinib vs ven obi for tn cll
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
2:04
rapid development in the cll treatment landscape